Literature DB >> 15626951

Population immunity to polioviruses among preschool children from four urban underserved low income communities, United States, 1997-2001.

D Rebecca Prevots1, F Brian Pascual, Mary Lu Angellili, Robert Brayden, Matilde Irigoyen, Philip Larussa, Mark Sawyer, Andrew L Baughman, Mark A Pallansch.   

Abstract

BACKGROUND: In 1997, the Advisory Committee for Immunization Practices (ACIP) recommended a change in polio vaccination policy, the first in 30 years, from the oral poliovirus vaccine (OPV) to a combined OPV/inactivated poliovirus vaccine (IPV) sequential schedule for routine childhood vaccination. To evaluate the impact of the change in polio vaccination schedule on population immunity, we conducted a seroprevalence survey among low income preschool children from selected urban areas.
METHODS: A repeat cross-sectional serosurvey was conducted during 1997-2001. Children 19-35 months of age receiving well-child care were recruited from outpatient clinics of academic medical centers. Serum samples were obtained and tested for neutralizing antibodies to polioviruses types 1, 2 and 3. A standardized questionnaire was administered to the parents or guardians of enrolled children.
RESULTS: Seroprevalence remained high and stable during the study period. Among children sampled in the last study year (initiating their vaccinations from August 1997 through September 2000), seroprevalence was >/=95% to poliovirus serotypes 1 and 2 and >/=94% to serotype 3. Overall coverage with >/=3 doses of polio vaccine was 82-95% across sites during this period. The proportion initiating their vaccination schedule with IPV increased from 2.6% in study year 1 (children born October 1994-January 1997) to 80% in study year 4 (children born October 1997-January 2000).
CONCLUSIONS: Children in these underserved low income communities are well-protected against the spread of polioviruses; the introduction of IPV did not adversely impact coverage or seroprevalence. Continued monitoring is needed to evaluate population immunity in the absence of OPV circulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15626951

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  4 in total

1.  Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response.

Authors:  Kimberly M Thompson; Gregory S Wallace; Radboud J Duintjer Tebbens; Philip J Smith; Albert E Barskey; Mark A Pallansch; Kathleen M Gallagher; James P Alexander; Gregory L Armstrong; Stephen L Cochi; Steven G F Wassilak
Journal:  Public Health Rep       Date:  2012 Jan-Feb       Impact factor: 2.792

2.  Seroprevalence of poliovirus antibodies in the Kansas City metropolitan area, 2012-2013.

Authors:  Gregory S Wallace; Barbara A Pahud; William C Weldon; Aaron T Curns; M Steven Oberste; Christopher J Harrison
Journal:  Hum Vaccin Immunother       Date:  2017-01-06       Impact factor: 3.452

3.  Seroprevalence of Poliovirus Antibodies in the United States Population, 2009-2010.

Authors:  Gregory S Wallace; Aaron T Curns; William C Weldon; M Steven Oberste
Journal:  BMC Public Health       Date:  2016-08-05       Impact factor: 3.295

4.  Oral polio vaccine response in the MAL-ED birth cohort study: Considerations for polio eradication strategies.

Authors:  William K Pan; Jessica C Seidman; Asad Ali; Christel Hoest; Carl Mason; Dinesh Mondal; Stacey L Knobler; Pascal Bessong
Journal:  Vaccine       Date:  2018-11-12       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.